Stockreport
Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress [Yahoo! Finance]
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
- Long-term extension data from LIVMARLI PFIC studies highlight improvement in key liver markers and growth FOSTER CITY, Calif., June 06, 2024 BUSINESS WIRE )--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that data from new analyses showing long-term treatment with LIVMARLI were presented during the European Association for the Study of the Liver (EASL) Annual Congress, June 5-8, 2024, in Milan, Italy. Presentations from studies evaluating LIVMARLI® (maralixibat) oral solution in patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) included: THU-094: Clinical Benefits with Maralixibat for Patients with Alagille Syndrome are Durable Through 7 Years of Treatment: Data from the MERGE Study Presented by Doug Mogul, MD, PhD – Mirum Pharmaceuticals, Inc., Foster City, CA, USA An analysis of ALGS studies evaluating LIVMARLI for up to seven years of treatment were presented to demonstrate the durability of response to LIVMARLI acro
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | MIRM | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
MIRM alerts
MIRM alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
NEWS
NEWS
- Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock? [Yahoo! Finance][Yahoo! Finance]
- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target raised by analysts at HC Wainwright from $58.00 to $66.00. They now have a "buy" rating on the stock.[MarketBeat]
- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target raised by analysts at Robert W. Baird from $34.00 to $39.00. They now have an "outperform" rating on the stock.[MarketBeat]
- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $48.00 price target on the stock.[MarketBeat]
- Mirum's Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies [Yahoo! Finance][Yahoo! Finance]
- More
MIRM
SEC Filings
SEC Filings
- 6/17/24 - Form 8-K
- 6/7/24 - Form 4
- 6/7/24 - Form 4
- MIRM's page on the SEC website
- More